Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MABEL CTLs
- Development stage
- Phase 1
- Lead developer
- Texas Children's Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
MABEL CTLs are a type of investigational cell therapy consisting of cytotoxic T lymphocytes (CTLs) specifically engineered to target and eliminate cells infected with the Epstein Barr Virus (EBV). These CTLs are generated from healthy donors and are trained to recognize three key EBV proteins: LMP, BARF-1, and EBNA1. They are being investigated for the treatment of various EBV-associated malignancies, including Hodgkin Disease, Non-Hodgkin Lymphoma, T/NK-lymphoproliferative disease, Severe Chronic Active Epstein Barr Virus, Nasopharyngeal Carcinoma, Smooth Muscle Tumor, and Leiomyosarcoma. The therapy involves infusing these banked, partially matched CTLs into patients.
02
Targets
BARF1 (Epstein-Barr virus BARF1 protein)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on MABEL CTLs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MABEL CTLs.